2012-10-09 07:05:16 -

Regulated information
                                                                 October 9, 2012


   TiGenix announces publication of Cx601 Phase I/IIa study in International
                         Journal of Colorectal Disease

Leuven  (BELGIUM) - October 9, 2012 - TiGenix (Euronext Brussels: TIG)   announced
today  the publication in the International Journal of Colorectal Disease of the
Phase  I/II  study  of  Cx601:  Expanded  allogeneic adipose-derived stems cells
(eASCs)  for  the  treatment  of  complex  perianal  fistula in Crohn's disease:
results from a multicenter phase I/II clinical trial.

The  authors of the study state that the  full analysis of efficacy data at week
24 showed  69.2% of  the  patients  with  a  reduction in the number of draining
fistulas,  while 56.3% of the patients achieved  complete closure of the treated
fistula, and 30% of the cases presented complete closure of all existing fistula
tracts.  The study, which  is published online  ahead of print,  can be accessed
here:  www.springerlink.com/content/j6k615530320kr02/

"We  are delighted with  the publication in  a reputed clinical  journal of this
study  that confirms  the significant  benefit of  our lead  development product
Cx601  in  a  very  challenging  indication  for  which  current  treatments are
suboptimal,"  said  Eduardo  Bravo,  CEO  of  TiGenix. "The publication of these
results  in a peer-reviewed journal  is a validation of  the thoroughness of our
development  program and demonstrates the  increasing prominence of cell therapy
as  an accepted clinical strategy that has the potential to considerably improve
on existing treatments paradigms."

Cx601  is  an  adipose-derived  allogeneic  stem  cell therapy that is delivered
locally  in  the  fistula  through  intra-lesional injection. Cx601 is currently
being investigated in the ADMIRE-CD Phase III study. ADMIRE-CD is a multicenter,
randomized,  double-blind,  placebo-controlled  Phase  III  trial  of  Cx601  in
approximately  278 Crohn's  disease  patients  suffering  from  complex perianal
fistulas.  The  main  objectives  of  the  study  are  to demonstrate safety and
superior  efficacy over placebo in perianal fistulas in Crohn's disease patients
after  failure with their previous treatment,  in most cases biologicals, and to
confirm the strong safety and efficacy results from the Phase II trial completed
in 2011. The results from ADMIRE-CD are expected in H2, 2014. Information on the
ADMIRE-CD trial can be found at www.clinicaltrials.gov.


For more information:
Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com

Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com

Hans Herklots
hans.herklots@tigenix.com
+32 16 39 60 97




About TiGenix

TiGenix  NV (Euronext Brussels: TIG) is  a leading European cell therapy company
with  a  marketed  product  for  cartilage  repair, ChondroCelect®, and a strong
pipeline  with  clinical  stage  allogeneic  adult  stem  cell  programs for the
treatment  of autoimmune  and  inflammatory  diseases.  TiGenix  is based out of
Leuven  (Belgium) and has operations in  Madrid (Spain), and Sittard-Geleen (the
Netherlands). For more information please visit www.tigenix.com.


Forward-looking information

This  document may contain forward-looking statements and estimates with respect
to  the anticipated  future performance  of TiGenix  and the  market in which it
operates. Certain of these statements, forecasts and estimates can be recognised
by  the use  of words  such as,  without limitation,  "believes",
"anticipates",
"expects",   "intends",   "plans",   "seeks", 
"estimates",  "may",  "will"  and
"continue"  and  similar  expressions.  They  include  all  matters that are not
historical  facts. Such statements, forecasts and estimates are based on various
assumptions  and assessments of known and unknown risks, uncertainties and other
factors,  which were deemed reasonable when made but  may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix' control. Therefore, actual results, the financial condition,
performance  or achievements of TiGenix, or industry results, may turn out to be
materially  different  from  any  future  results,  performance  or achievements
expressed  or implied by  such statements, forecasts  and estimates. Given these
uncertainties,  no representations  are made  as to  the accuracy or fairness of
such  forward-looking statements, forecasts and estimates. Furthermore, forward-
looking  statements, forecasts and  estimates only speak  as of the  date of the
publication  of this  document. TiGenix  disclaims any  obligation to update any
such  forward-looking statement, forecast or estimates  to reflect any change in
TiGenix'  expectations with regard thereto, or  any change in events, conditions
or  circumstances on  which any  such statement,  forecast or estimate is based,
except to the extent required by Belgian law.




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: TiGenix via Thomson Reuters ONE
[HUG#1647357]